Have a Topic Idea?

What would you like to see featured on MedConnect? Let us know.

Submit an Idea

MedImpact Holds 2016 Annual Trend to 2.9 Percent

MedImpact, an independent, trend-focused PBM, held its 2016 overall annual trend to a mere 2.9 percent. The MedImpact Annual Trend Report examined the annual trend by...

Biosimilars: The Challenges and The Opportunities

Biosimilar drugs present a large potential for reducing specialty spending, but their instability and sensitivity to manufacturing present challenges as well. Biosimilars...

Examining Drug Trend: HIV

Drug price drove 2016 trend. Overall utilization for the top 10 therapeutic classes in 2016 decreased, while prices increased. To better understand 2016 trend, we will...

Drug Information Update- Mavyret (glecaprevir/pibrentasvir)

Mavyret (glecaprevir/pibrentasvir) New Drug Approval: On August 3, 2017 the FDA approved Mavyret for the treatment of adult patients with chronic...

National Drug Take Back Day Yields 450 TONS of Unused Medications

Rise in Prescription Waste is Costing Unnecessary Money Saturday, April 29 was Drug Take Back Day, where unused drugs were returned in droves to designated Drug...

Examining Drug Trend: Hepatitis C

Top 10 Classes - What is Driving Drug Trend Drug price is driving trend. Overall utilization for the top 10 therapeutic classes in 2016 decreased, while prices...

Examining Drug Trend: Oncology

Top 10 Classes - What is Driving Drug Trend Drug price is driving trend. Overall utilization for the top 10 drug classes in 2016 decreased, while prices increased....

Examining Drug Trend: Inflammatory Disease

Drug price is driving trend. Overall utilization for the top 10 drug classes in 2016 decreased, while prices increased. To better understand 2016 trend, we will be...

Examining Drug Trend: Diabetes

Drug price is driving trend. Overall utilization for the top 10 drug classes in 2016 decreased, while prices increased. To better understand 2016 trend, we will be...

Drug Information Update- Ocrevus (ocrelizumab)

Ocrevus (ocrelizumab) New Drug Approval: On March 28 th , 2017 the FDA approved Ocrevus (ocrelizumab) to treat adult patients with relapsing forms of...

Drug Information Update- Kisqali (ribociclib)

Kisqali (ribociclib) New Drug Approval: On March 13 th , 2017 the FDA approved Kisqali (ribociclib) in combination with an aromatase inhibitor as initial...

Drug Inflation in the News: EpiPen

With drug inflation at the forefront of trend concerns in the pharmacy benefit industry, the rise in cost of drugs like the EpiPen have gained lots of press coverage in...

5 Reasons You Won’t Want to Miss The MedImpact Annual Conference

  The MedImpact conference is only 5 weeks away! Don’t miss out on the opportunity to hear from industry experts on all the hot topics affecting...

Drug Information Update- Exondys 51 (eteplirsen)

New Drug Approval: On September 19 th , 2016 the FDA approved Exondys 51 (eteplirsen) for the treatment of Duchenne Muscular Dystrophy (DMD) in patients who...

Drug Information Update- Amjevita (adalimumab-atto)

New Drug Approval: On September 23 rd , 2016 the FDA approved Amjevita (adalimumab-atto), a biosimilar for Humira, for rheumatoid arthritis (RA), psoriatic...

Drug Information Update- Basaglar (insulin glargine)

New Drug Approval - Basaglar (insulin glargine) FDA Approval: In December 2015, the FDA approved Basaglar (insulin glargine), a long-acting human insulin...

Combating Opioid Waste and Abuse

Opioids are now the leading cause of accidental death in the U.S . According to the Center for Disease Control (CDC), there were a total of 47,055 lethal drug overdoses...

The 2015 Annual Trend Report is Here

MedImpact has released its 2015 Annual Trend Report. The purpose of this report is to provide a better understanding of the proactive strategies and solutions we can help...

Specialty Drug Pricing and Channeling

For years pharmaceutical manufacturers have defended the high cost of newly approved medications with explanations about the skyrocketing costs of research and development. In the current...

MedMatters

Latest announcements and news from MedImpact. Updated December 2015.